Значение опиоидной системы кишечника и способы лекарственного воздействия на нее

1. Гомазков О. А. Нейропептиды – универсальные регуляторы. Почему? Природа. 1999; 4: 5–10.
2. Shahbazian A, Heinemann А, Schmidhamme Н et al. Involvement of карра-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Brit J Pharmacol 2002; 135: 741–50.
3. Baker DE. Loperamide: a pharmacological review. Rev Gastroenterol Disord 2007; 7 (Suppl. 3): S11–8.
4. Bileviciute-Ljungar I, Saxne T, Spetea M. Anti-inflammatory effects of contralateral administration of the ?-opioid agonist U-50,488H in rats with unilaterally induced adjuvant arthritis. Rheumatology 2006; 45 (3): 295–302.
5. Black D, Trevethick M. The kappa opioid receptor is associated with the perception of visceral pain. Gut 1998; 43: 312–3 doi:10.1136/gut.43.3.312.
6. Bueno L, Fioramonti J. Action of opiates on gastrointestinal function. Baillieres Clin Gastroenterol 1988; 2 (1): 123–39.
7. Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 1999; 13 (Suppl. A): 71A–5A.
8. Corazziari E. Role of opioid ligands in the irritable bowel syndrome. J Gastroenterol Hepatol 2004; 19 (7): 744–9.
9. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 1997; 25 (5): 225–46.
10. De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16 (4): 383–94.
11. Ehrenpreis ED, Chang D, Eichenwald E. Pharmacotherapy for fecal incontinence: a review. Dis Colon Rectum 2007; 50 (5): 641–9.
12. Hanauer SB. The role of loperamide in gastrointestinal disorders. Rev Gastroenterol Disord 2008; 8 (1): 15–20.
13. Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 2004; 361 (1–3): 192–5.
14. King RFGJ, Hill GH. Effect of loperomide and codeine phosphate on ileostomy output. Clin Res Rev 1981; 1 (Suppl. 1): 207–13.
15. Kromer W, Schmidt H. Opioids modulate intestinal peristalsis at a site of action additional to that modulating acetylcholine release. Pharmacology 1982; 223 (1): 271–4.
16. Levitt MD, Jenner DC, Maher MJ. High dose loperamide suppositories: a novel approach for improving clinical function after restorative proctocolectomy. Aust N Z J Surg 1995;
65 (12): 881–3.
17. L . . K. A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. Curr Med Res Opin 1980; 6 (6): 437–43.
18. Moshal MG, Herron M. A clinical trial of trimebutine (Mebutin) in spastic colon. J Int Med Res 1979; 7 (3): 231–4.
19. Nightingale J, Woodward JM. Small Bowel and Nutrition Committee of the British Society of Gastroenterology. Guidelines for management of patients with a short bowel. Gut 2006; 55 (Suppl. 4): iv1–12.
20. Shah SB, Hanauer SB. Treatment of diarrhea in patients with inflammatory bowel disease: concepts and cautions. Rev Gastroenterol Disord 2007; 7 (Suppl. 3): S3–10.
21. Shee CD, Pounder RE. Loperamide, diphenoxylate, and codeine phosphate in chronic diarrhea. Br Med J 1980; 280 (6213): 524.
22. Schmidt T, Hackelsberger N, Widmer R et al. Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 1996; 31 (6):
581–9.
23. Tytgat GN, Huibregtse K. Loperamide and ileostomy output-placebo-controled double-blind crossover study. Br Med J 1975; 2 (5972): 667.
24. Tytgat GN, Huibregtse K, Dagevos J, van den Ende A. Effect of loperamide on fecal output and composition in well-established ileostomy and ileorectal anastomosis. Am J Dig Dis 1977; 22 (8): 669–76.
25. Tijtgat GN, Meuwissen SG, Huibregtse K. Loperamide in the symptomatic control of chronic diarrhoea. Double-blind placebo-controlled study. Ann Clin Res 1975; 7 (5):
325–30.
26. Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol 2003; 521: 148–60.
27. Ziegenhagen DJ, Kruis W. Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo. Can J Gastroenterol 1999; 13 (Suppl. A):
71A–5A.